JP2021506794A - 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤 - Google Patents

疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤 Download PDF

Info

Publication number
JP2021506794A
JP2021506794A JP2020532629A JP2020532629A JP2021506794A JP 2021506794 A JP2021506794 A JP 2021506794A JP 2020532629 A JP2020532629 A JP 2020532629A JP 2020532629 A JP2020532629 A JP 2020532629A JP 2021506794 A JP2021506794 A JP 2021506794A
Authority
JP
Japan
Prior art keywords
seq
magi
pain
peptide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020532629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506794A5 (https=
Inventor
バッターチャルジー，アリンダム
プライス，ケリー
Original Assignee
ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク, ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク filed Critical ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Publication of JP2021506794A publication Critical patent/JP2021506794A/ja
Publication of JP2021506794A5 publication Critical patent/JP2021506794A5/ja
Priority to JP2023195583A priority Critical patent/JP2024026109A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • C12Y207/04008—Guanylate kinase (2.7.4.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020532629A 2017-12-13 2018-12-13 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤 Pending JP2021506794A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023195583A JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598067P 2017-12-13 2017-12-13
US62/598,067 2017-12-13
PCT/US2018/065545 WO2019118779A2 (en) 2017-12-13 2018-12-13 Peptides and other agents for treating pain and increasing pain sensitivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023195583A Division JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Publications (2)

Publication Number Publication Date
JP2021506794A true JP2021506794A (ja) 2021-02-22
JP2021506794A5 JP2021506794A5 (https=) 2022-01-06

Family

ID=66820711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020532629A Pending JP2021506794A (ja) 2017-12-13 2018-12-13 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤
JP2023195583A Pending JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023195583A Pending JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Country Status (8)

Country Link
US (3) US11535649B2 (https=)
EP (1) EP3723781B1 (https=)
JP (2) JP2021506794A (https=)
CN (1) CN111712252A (https=)
AU (1) AU2018383669B2 (https=)
CA (1) CA3085576A1 (https=)
IL (1) IL275340A (https=)
WO (1) WO2019118779A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085576A1 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity
BR112022006862A2 (pt) * 2019-10-10 2022-07-05 Univ New York State Res Found Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
WO2025102083A1 (en) * 2023-11-12 2025-05-15 The Research Foundation For The State University Of New York Compositions and methods for treating pain or for increasing pain sensitivity
WO2025123001A1 (en) * 2023-12-08 2025-06-12 Washington University Targeted protein degradation compositions and methods of use thereof for pain control

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011254A1 (en) * 1996-09-10 1998-03-19 Arch Development Corporation MUTATIONS IN THE DIABETES SUSCEPTIBILITY GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA (α), HNF-1β AND HNF-4$g(a)
WO2000056772A1 (en) * 1999-03-25 2000-09-28 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
WO2003029821A1 (en) * 2001-10-01 2003-04-10 Buck Institute Target assisted iterative screening (tais) : a novel screening format for large molecular repertoires
JP2014533245A (ja) * 2011-11-04 2014-12-11 リポテック， エセ．ア． 活性化受容体を阻害するペプチド、および化粧品組成物または薬学的組成物におけるそれらの使用
US20160222071A1 (en) * 2010-07-07 2016-08-04 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
WO2017147379A1 (en) * 2016-02-26 2017-08-31 The Johns Hopkins University Pharmacological modulators of nav1.1 voltage-gated sodium channels associated with mechanical pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1252330A2 (en) 1999-11-26 2002-10-30 McGill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
US20030216310A1 (en) 2001-05-25 2003-11-20 Thornton Michael B. Transporters and ion channels
US20090087436A1 (en) 2001-07-13 2009-04-02 Myriad Genetics, Incorporated Compositions and methods for treating diseases
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
WO2005059101A2 (en) 2003-12-12 2005-06-30 Wyeth Novel sodium channel
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005118614A1 (en) * 2004-04-08 2005-12-15 Avigen, Inc. Methods and compositions for treating neuropathic pain
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
JP2010529966A (ja) 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
WO2009006555A2 (en) 2007-07-02 2009-01-08 Yu, Ming Methods, composition, targets for combinational cancer treatments
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
DK2307035T3 (da) 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
JP2012503619A (ja) 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
EP2275545A1 (en) 2009-07-16 2011-01-19 Julius-Maximilians-Universität Würzburg Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
EP2478002B1 (en) * 2009-09-18 2015-02-25 University Of Houston Small peptide modulators of potassium channel trafficking
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
EP2616094B1 (en) 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
WO2012135666A1 (en) 2011-04-01 2012-10-04 University Of Louisiana At Monroe Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CA3085576A1 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011254A1 (en) * 1996-09-10 1998-03-19 Arch Development Corporation MUTATIONS IN THE DIABETES SUSCEPTIBILITY GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA (α), HNF-1β AND HNF-4$g(a)
WO2000056772A1 (en) * 1999-03-25 2000-09-28 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
WO2003029821A1 (en) * 2001-10-01 2003-04-10 Buck Institute Target assisted iterative screening (tais) : a novel screening format for large molecular repertoires
US20160222071A1 (en) * 2010-07-07 2016-08-04 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
JP2014533245A (ja) * 2011-11-04 2014-12-11 リポテック， エセ．ア． 活性化受容体を阻害するペプチド、および化粧品組成物または薬学的組成物におけるそれらの使用
WO2017147379A1 (en) * 2016-02-26 2017-08-31 The Johns Hopkins University Pharmacological modulators of nav1.1 voltage-gated sodium channels associated with mechanical pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K. D. PRYCE: "The scaffold protein Magi-1 regulates voltage-dependent sodium channels in dorsal rott ganglion neur", NEUROSCIENCE 2017 [ONLINE], JPN6022044105, 13 November 2017 (2017-11-13), ISSN: 0004900191 *

Also Published As

Publication number Publication date
WO2019118779A3 (en) 2019-07-25
US20230046305A1 (en) 2023-02-16
US11535649B2 (en) 2022-12-27
US20200369726A1 (en) 2020-11-26
EP3723781B1 (en) 2024-12-11
AU2018383669A1 (en) 2020-07-02
EP3723781A4 (en) 2021-07-21
AU2018383669B2 (en) 2023-05-18
CN111712252A (zh) 2020-09-25
US12077610B2 (en) 2024-09-03
JP2024026109A (ja) 2024-02-28
WO2019118779A2 (en) 2019-06-20
US20250154199A1 (en) 2025-05-15
EP3723781A2 (en) 2020-10-21
CA3085576A1 (en) 2019-06-20
IL275340A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
US12077610B2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
Zhao et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory
Bi et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension
Cao et al. Expression of nerve growth factor carried by pseudotyped lentivirus improves neuron survival and cognitive functional recovery of post‐ischemia in rats
EP3622958B1 (en) Use of potassium ion channel inhibitor for treatment of depression and pharmaceutical composition
DK2904009T3 (en) RELATIONSHIPS FOR TREATING THE REMYELINIZATION BLOCK IN DISEASES RELATED TO THE EXPRESSION OF HERV-W COAT PROTEIN
Xi et al. Intraventricular injection of LKB1 inhibits the formation of diet-induced obesity in rats by activating the AMPK-POMC neurons-sympathetic nervous system axis
US10640768B2 (en) Method of treating pain with an antibody against netrin-4, UNC5B or neogenin
Lai et al. CtBP1 is essential for epigenetic silencing of μ-opioid receptor genes in the dorsal root ganglion in spinal nerve ligation-induced neuropathic pain
US20240294571A1 (en) Analgesic and anesthetic peptides and other agents
Andino et al. POMC overexpression in the ventral tegmental area ameliorates dietary obesity
HK40037093A (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK40037093B (en) Peptides and other agents for treating pain and increasing pain sensitivity
US20190381125A1 (en) Methods of Treating Angiogenesis-Related Disorders Using JNK3 Inhibitors
US20230218631A1 (en) G9a inhibition decreases stress-induced and dependence-induced escalation of alcohol drinking
CA3069179A1 (en) Targeting the hdac2-sp3 complex to enhance synaptic function
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
Testa Understanding Pain Construction from Nociception through a Novel Mutation in Nerve Growth Factor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231120

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231208

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240112